

Ramon Andrade de Mello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7008482/ramon-andrade-de-mello-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

1,149
citations

21
h-index

31
g-index

92
ext. papers

1,393
ext. citations

3.6
avg, IF

4.59
L-index

#	Paper	IF	Citations
76	Screening for Colorectal Cancer Leading into a New Decade: The "Roaring 20s" for Epigenetic Biomarkers?. <i>Current Oncology</i> , 2021 , 28, 4874-4893	2.8	1
75	Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
74	CRISPR-based strategies in infectious disease diagnosis and therapy. <i>Infection</i> , 2021 , 49, 377-385	5.8	5
73	Current and potential biomarkers in gastric cancer: a critical review of the literature. <i>Future Oncology</i> , 2021 , 17, 3383-3396	3.6	3
72	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.. <i>Cancers</i> , 2021 , 14,	6.6	2
71	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	15
70	The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
69	MiR-139-5p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020 , 1866, 1657-1677	6.9	21
68	Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitinib for advanced renal cell carcinoma in the U.K. Perspective.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 689-689	2.2	1
67	MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?. <i>Current Genomics</i> , 2020 , 21, 372-381	2.6	1
66	PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?. <i>Future Oncology</i> , 2019 , 15, 1407-1410	3.6	2
65	Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 237-247	7.1	11
64	Assessing treatment benefits with CDK4/6i+ET for hormone receptor-positive advanced breast cancer: A network meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12543-e12543	2.2	
63	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2019 , 129, 223-229	15.9	62
62	Lung cancer: a brief review of epidemiology and screening. <i>Future Oncology</i> , 2018 , 14, 567-575	3.6	15
61	Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. <i>Immunotherapy</i> , 2018 , 10, 887-897	3.8	7
60	What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 249-261	7.1	2

59	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. <i>Oncotarget</i> , 2018 , 9, 11805-11815	3.3	7
58	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. <i>Immunotherapy</i> , 2017 , 9, 499-506	3.8	122
57	The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. <i>Annals of Oncology</i> , 2017 , 28, 2256-2263	10.3	54
56	The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer. <i>Future Oncology</i> , 2017 , 13, 2045-2051	3.6	8
55	MicroRNAs in lung cancer. <i>Oncotarget</i> , 2017 , 8, 81679-81685	3.3	68
54	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <i>ESMO Open</i> , 2017 , 2, e000200	6	25
53	Gastric Cancer in Southern Europe: High-Risk Disease. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 261-266	7.1	2
52	Economic impact of immune checkpoint inhibitor therapy in Brazil and strategies to improve access.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6612-6612	2.2	1
51	Epigenetic therapy in urologic cancers: an update on clinical trials. <i>Oncotarget</i> , 2017 , 8, 12484-12500	3.3	27
50	The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior 2017 , 217-239		
49	Epigenetic regulation of cancer self-renewal differs between endocrine tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15717-e15717	2.2	
48	Potential role of immunotherapy in advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 21-30	4.4	33
47	Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. <i>Future Oncology</i> , 2016 , 12, 2755-2764	3.6	6
46	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016 , 12, 551-64	3.6	7
45	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016 , 8, 479-88	3.8	105
44	Current advances in targeted therapies for metastatic gastric cancer: improving patient care. <i>Future Oncology</i> , 2016 , 12, 839-54	3.6	2
43	Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9033-9033	2.2	0
42	EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016 , 11, 393-400	2.6	5

41	5-fluorouracil-leucovorin chemoradiotherapy to the adjuvant treatment of operable gastric cancer: A retrospective data from a Brazilian reference cancer institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15540-e15540	2.2	
40	TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016 , 4, 185	3.2	
39	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. <i>Immunotherapy</i> , 2016 , 8, 681-6	3.8	1
38	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. <i>Immunotherapy</i> , 2016 , 8, 1011-9	3.8	28
37	Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. <i>Pharmacogenomics</i> , 2015 , 16, 257-71	2.6	21
36	Immunotherapy for lung cancer: for whom the bell tolls?. <i>Tumor Biology</i> , 2015 , 36, 1411-22	2.9	14
35	Nivolumab for advanced squamous cell lung cancer: what are the next steps?. <i>Lancet Oncology, The</i> , 2015 , 16, 234-5	21.7	12
34	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. <i>Annals of Translational Medicine</i> , 2015 , 3, 81	3.2	9
33	Palliative sedation in terminal cancer patients with refractory uncontrolled symptoms.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20551-e20551	2.2	
32	Challenges in Lung Cancer Approaches: from the Clinical Issues to the Novel Therapies. <i>Recent Advances in DNA & Gene Sequences</i> , 2015 , 9, 45-50		
31	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution. <i>PLoS ONE</i> , 2014 , 9, e86697	3.7	31
30	Knee glomangioma: a rare location for a glomus tumor. <i>Rare Tumors</i> , 2014 , 6, 5588	1.1	8
29	Immunotherapy and lung cancer: current developments and novel targeted therapies. <i>Immunotherapy</i> , 2014 , 6, 1221-35	3.8	41
28	Genetic polymorphisms and non-small-cell lung cancer: future paradigms. <i>Einstein (Sao Paulo, Brazil)</i> , 2014 , 12, 524-6	1.2	4
27	BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy. <i>Molecular Diagnosis and Therapy</i> , 2014 , 18, 285-91	4.5	8
26	Personalizing medicine for metastatic colorectal cancer: current developments. <i>World Journal of Gastroenterology</i> , 2014 , 20, 10425-31	5.6	11
25	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2013 , 14, 1765-77	2.6	31
24	HER2 therapies and gastric cancer: a step forward. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6165-9	5.6	35

23	The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer. <i>PLoS ONE</i> , 2013 , 8, e72373	3.7	23
22	Loci identified through genome-wide association studies and lung cancer risk: is there anything more?. <i>Sao Paulo Medical Journal</i> , 2013 , 131, 135-6	1.6	5
21	Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6383-97	5.6	21
20	Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7955-71	5.6	26
19	Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy. <i>Clinics</i> , 2013 , 68, 726	2.3	2
18	Role of Genetic Polymorphisms in the Angiogenesis Pathway and Non-small-Cell Lung Cancer Tumor Behavior: Implications in Risk Assessment and Clinical Outcome 2013 , 381-403		3
17	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. <i>Tumor Biology</i> , 2012 , 33, 2061-8	2.9	24
16	Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. <i>Tumor Biology</i> , 2012 , 33, 1341-8	2.9	15
15	Personalizing medicine: strategies for implementing the evaluation of anaplastic lymphoma kinase rearrangement in non-small-cell lung cancer in Portugal. <i>Revista Portuguesa De Pneumologia</i> , 2012 , 18, 244-6		6
14	Stridor and respiratory failure due to tracheobronchomalacia: case report and review of the literature. <i>Sao Paulo Medical Journal</i> , 2012 , 130, 61-4	1.6	1
13	Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies. <i>Recent Patents on DNA & Gene Sequences</i> , 2012 , 6, 56-63		5
12	Metastatic melanoma and vemurafenib: novel approaches. <i>Rare Tumors</i> , 2012 , 4, e31	1.1	1
11	Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2012 , 7, 118-31	2.6	24
10	Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices. <i>Clinics</i> , 2012 , 67, 1349	2.3	4
9	Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2012 , 6, 163-6	2.9	12
8	Sacrum osteosarcoma after pelvic radiation for uterine cervical cancer: highlighted issues. <i>Sao Paulo Medical Journal</i> , 2012 , 130, 344-5	1.6	0
7	Back to EGF+61 genetic polymorphisms and lung cancer risk: looking to the future!. <i>Sao Paulo Medical Journal</i> , 2012 , 130, 415-6	1.6	1
6	Chylous ascites due to signet ring cell gastric adenocarcinoma. <i>Nigerian Journal of Clinical Practice</i> , 2012 , 15, 487-90	1	2

5	Renal failure due to primary amyloidosis: a case report and literature review. <i>Sao Paulo Medical Journal</i> , 2011 , 129, 176-80	1.6	2
4	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. <i>World Journal of Clinical Oncology</i> , 2011 , 2, 367-76	2.5	31
3	Multiple-system atrophy with cerebellar predominance presenting as respiratory insufficiency and vocal cords paralysis. <i>Case Reports in Medicine</i> , 2010 , 2010,	0.7	3
2	Hemophagocytic Syndrome Associated with Hodgkin's Lymphoma First Presenting as Fever and Pancytopenia. <i>Case Reports in Medicine</i> , 2010 , 2010, 759651	0.7	3
1	Concurrent breast stroma sarcoma and breast carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2010 , 4, 414	1.2	2